Spyre Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Spyre Therapeutics, Inc.'s free cash flow has decreased 7.52% from $-157.41M last year to $-169.25M, signaling decreasing performance

Spyre Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Spyre Therapeutics, Inc. has insufficient data to evaluate this check.

Spyre Therapeutics, Inc. has a net cash position, so leverage is healthy.

Spyre Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Spyre Therapeutics, Inc. has insufficient data to evaluate this check.

Spyre Therapeutics, Inc.'s short-term assets of $777.78M exceed its short-term liabilities of $58.69M

Spyre Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Spyre Therapeutics, Inc.'s return on equity of -24.32%, is lower than 15.00%, indicating bad performance

Spyre Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Spyre Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Spyre Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Spyre Therapeutics, Inc. has negative free cash flow, indicating cash burn

Spyre Therapeutics, Inc.'s yearly earnings has increased -25.39% since last year from $-208.02M to $-155.20M, signaling increasing performance

Spyre Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -18.14% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Spyre Therapeutics, Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Spyre Therapeutics, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Spyre Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Spyre Therapeutics, Inc. has insufficient data to evaluate this check.

Spyre Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Spyre Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Spyre Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Spyre Therapeutics, Inc. has insufficient data to evaluate this check.

Spyre Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Spyre Therapeutics, Inc. has a price-to-book ratio of 8.10x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Spyre Therapeutics, Inc. has a price-to-sales ratio of 98.62x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue